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Epidermolysis bullosa acquisita (EBA) of the immu-
nopathological type is a distinct disease entity which we 
propose to name dermolytic pemphigoid. Clinical fea-
tures of this disease are heterogeneous. An inflamma-
tory phase may mimic bullous pemphigoid or, less com-
monly, mucosal pemphigoid or dermatitis herpetiformis. 
The noninflammatory mechanobullous phase equates 
with classic EBA and features marked skin fragility, 
bullae and/or erosions at sites of trauma, which result 
in scarring and milia. The inflammatory or the nonin-
flammatory phase may occur separately or in combina-
tion. Transition from inflammatory to noninflammatory 
phases has been seen. Linear basement membrane zone 
(BMZ) immune deposits of immunoglobulin G (lgG) are 
present in the lesional and uninvolved skin of affected 
patients by immunofluorescence and are essential for 
the diagnosis. Many patients also have circulating anti-
basement membrane zone lgG antibodies. lmmunoelec-
tron microscopy localizes the immune deposits in the 
lamina densa and sublamina densa zone and serves to 
distinguish this disease from diseases with lamina Iucida 
antibodies, such as bullous pemphigoid and mucosal 
pemphigoid. The EBA antigen has recently been identi-
fied and partially characterized from human skin using 
circulating antibasement membrane zone antibodies 
from patients with EBA. The EBA antigen consists of 2 
components of Mr 290,000 and 145,000, and were 
shown to be distinct from other known basement mem-
brane components. Mouse monoclonal antibody, H3a, 
recognizes the same 290 kilodaltons (kd) and 145 kd 
proteins and localizes to the lamina densa and sublamina 
densa zone of human skin. The EBA antigen is a newly 
recognized basement membrane component that is re-
stricted in its distribution to the BMZ of stratified squa-
mous epithelium of both keratinizing a nd nonkeratin-
izing types. 
The term, epidermolysis bullosa acquisita (EBA) , was origi-
nally coined to categorize a rare group of patients with features 
of epidermolysis bullosa (EB) arising beyond the childhood 
period whose di sease was presumably acquired rather than 
This work was supported by National Institutes of Health grants 5-
R01-AM10546-18, 5-R01-AM30475-03, and l -R01-AM33625-0l. 
Reprint requests to: Robert A. Briggaman, M.D., Department of 
Dermatology, North Carolina Memorial Hospital, Chapel Hill, North 
Carolina 27514. 
Abbreviations: 
BMZ: basement membrane zone 
BP: bullous pemphigoid 
DH: dermatitis herpetiformis 
EB: epidermolysis bu llosa 
EBA: epidermolysis bullosa acquisita 
EBA-IP: EBA immunopathological type 
kd: kilodaltons 
MP: mucosal pemphigoid 
PCT: porphyria cutanea tarda 
SDS-PAGE: sodium dodecyl sulfate- polyacrylamide gel electro-
phoresis 
SLE: systemic lupus erythematosus 
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hereditary. From its inception, it seems likely that this broad 
designation encompassed a variety of entities. Attempts have 
been made to t ighten the definition of EBA. In 1971, Roenigk 
and colleagues [1] proposed the following clinical cri teria which 
included: (1) trauma-induced bullae over the hands, feet, elbows 
and knees, atrophic scars, milia, and nail dys~rophy, (2) adult 
onset, (3) absence of a family history of EB, and (4) exclusion 
of all other bullous diseases. Through t he years, specific dis-
eases t hat might have been included in EBA as defined above 
were removed following their recognition. Examples of t hese 
include bullous amyloidosis, various types of porphyria, por-
phyria cutanea tarda-like or EBA-like drug reactions to peni-
cillamine, furosemide, and nalidixic acid, and t he bullous erup-
tion of chronic dia lysis (pseudoporphyria) . 
During t he 1970's, some patients with EBA were reported 
with immunological features indistinguishable from t he subep-
idermal blistering diseases, bullous pemphigoid (BP) or mu-
cosal pemphigoid (MP) . These features included linear depo-
sit ion of immunoglobulin G (IgG) and complement components 
at the epidermal-dermal junct ion [2-10). In addition, some of 
these patients had circulating IgG ant ibasement membrane 
ant ibodies. Immunoelectron microscopic studies of these pa-
tients showed t hat t he immune deposits were below t he lamina 
densa and served to distinguish patients with EBA from other 
subepidermal blistering diseases such as BP or MP [11-16]. 
Revised criteria for the diagnosis of EBA included these im-
muno logical features [17]. Nevertheless, occasional patients 
continue to be seen with disease featuring t rauma-induced 
blisters, scarring, adul t onset, lack of a family history of EB, 
and in whom all other bullous diseases can be excluded. These 
patients lack any evidence of an immune etiology, amyloid, 
porphyria, or drug ingestion. The authors believe t hat a case 
can be made for retaining the generic term, epidermolysis 
bullosa acquisita, and separating out the immunopathological 
type (EBA-IP) as a new and distinctive disease ent ity t hat 
might be appropriately termed "dermolytic pemphigoid. " The 
criteria for this disease would be: (1) a chronic bullous disease, 
(2) subepidermal blisters, (3) linear deposits of IgG at t he BMZ, 
and (4) IgG deposits in the upper dermis beneath the lamina 
den sa. 
In the present study, t he clinical and immunological features 
of EBA of the immunopathological type (dermolytic pemphi-
goid) will be reviewed with special emphasis on the aut hors' 
own experience. Studies of the recent ly recognized EBA ant igen 
will also be reviewed. 
EPIDERMOLYSIS BULLOUS ACQUISITA-
IMMUNOPATHOLOGICAL TYPE (DERMOL YTIC 
PEMPHIGOID)- THE DISEASE 
Clinical Features 
One of the most notable features of t his disease is the 
variation in its clinica l features, presentation and course. The 
capacity of EBA to mimic other vesiculobullous disorders is a 
source of diagnostic and nosologic difficulties [18- 20]. Both 
inflammatory and noninflammatory (mechanobullous) phases 
of the disease may be seen separately or sometimes together in 
the same patient. The noninflammatory phase equates with 
"classic" EBA. Marked skin fragility and bullae and/or erosions 
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induced by minimal trauma are features of t he noninflamma-
tory phase. Scarring at s ites of previous blistering, especially 
t hose sites exposed to repeated blistering, is characteristic. 
Milia are frequently encountered and nail dystrophy and scar-
ring alopecia may be seen. The extent of t he disease is variable 
in different patients. Locali zed involvement, predominantly on 
t he dorsum of t he hands and a rms, may closely resemble 
porphyria cutanea tarda (PCT). More extensive involvement 
of t he acra l s ites, especially t he a rms, feet, hands, knees, and 
elbows, mimic t he find ings in dystrophic dominant ep idermo-
lysis bullosa (DDEB). Generalized cutaneous involvement s im-
ilar to that seen in ep idermolysis bullosa dystrophica-recessive 
(EBD-R) has been reported in about a third of t he reported 
cases. Oral mucous membrane involvement characterized by 
erosions and subsequent scarring may be seen in about half t he 
patients. Laryngea l, ocu la r, and esophageal mucosal involve-
ment may be seen. Resul tant scarring in t hese s ites has led to 
function al impairment, such as esophageal stenosis and loss of 
vis ion, similar to t he involvement t hat may be seen in t he 
severe forms of EB or MP . 
The recognition t hat EBA-IP may have an inflammatory 
phase as well as a noninflammatory mechanobullous phase is 
a relatively recent observation [14). Our experience indicates 
that an inflam mato ry phase of EBA-IP may be relatively 
common, espec ia lly in t he ea rly stage of t he disease (Table I, 
Cases 1- 5, 10, 11). The inflammatory phase may closely mimic 
BP or Jess commonly MP or dermatitis herpetiform is (DH). 
T he BP-like inflammatory presentation features a generalized 
bu llous eruption with large tense bullae t hat may involve t he 
llexura l and in tertriginous a reas. Spontaneous blisters arise on 
erythematous skin. In addit ion, macular and plaque-like ery-
thema, with or without blisters, may be seen. The lesions tend 
to hea l without sca rring or milia formation, at least initially. 
Patients have also been reported with features resembling 
MP, includ ing in flammation and scarring of t he conjunctiva, 
mouth , and other mucous membranes as well as involvement 
of t he skin on the head and neck. 
Vol. 85, No. 1 Supplement 
Course 
EBA-IP follows a chronic course, but exhibi ts great variation 
in its presentation and evolut ion. Many of our patien ts began 
with an inflammatory phase resembling BP (Table I, Cases 1-
5). One patient had persistent inflam matory lesions with no 
tendency to scar or form milia over a duration of two years' 
follow up (Table I, Case 4). In t he majority of patients beginning 
with an ini t ial inflammatory phase, a period of transition to 
the noninflammatory phase has occurred during which t he 
patients expe rienced both inflammatory and noninflammatory 
lesions (Table I, Cases 1-3). In severa l of our patients, t he 
disease was noninflammatory from its onset similar to the 
earlier descriptions of EBA (Table I, Cases 6-9, 12). 
A fair to poor response to t herapy has been emphasized 
previously as a feature characteristic for EBA-IP. Many pa-
tients have eit her failed to respond or responded only to high 
and persistent doses of glucocorticosteroids, immunosuppres-
sive or cytotoxic agents, and sulfones. However, some patients 
have responded to prednisone alone or a combination of pred-
nisone with a cytotoxic agent, so t hat a poor response to therapy 
with these agents is not invariably t he case. 
Associated Diseases 
EBA has been associated with numerous other disorders 
including systemic lupus erythematosus (SLE) , rheumatoid 
art hri t is, multiple myeloma, chronic t hyroidit is, diabetes mel-
li tus, lymphoma or lymphoma-like disorders, inflammatory 
bowel disease, amebic dysentery, pulmonary fibrosis, psoriasis, 
tubercu losis, carcinoma of t he lung, and cryoglobulinemia. In -
flammatory bowel disease and diabetes melli tus head t he list 
numerically. One of our patients had a multiple endocrinopathy 
syndrome that included Addison's disease, pernicious anemia, 
hypoparathyroidism, and interstitial nephriti s. The proposed 
autoimmune etiology for some of t he disorders t hat are associ-
ated with EBA- IP is interesting in light of the probable immune 
etiology ofEBA-IP. The special case of the association ofEBA-
IP and SLE will be discussed more fu lly later. 
TABLE I. Clinical Features 
Onset Duration Case age/sex (yrs) 
1 (CM) 44 F 4 
2 (OK) 61 F 2 
3 (EC) 51 F 2 
4 (IW) 51 F 2 
5 (OM) 77F 6 mos 
6 (CR) 51 M 3 
7 (WS) 71 M 3 
8 (JM) 36 M 2 
9 (AS) 50 M 10 
10 (JC) 27 M 6 
Jl (MM) 57 F 6 mos 
12 (MB) 72 F 1 
Inflammatory Mechanobullous 
phase phase 
BP-like PCT-like 
BP-like Generalized EB 
BP- like Generalized EB 
BP-like None 
BP- li ke Generalized EB 
scarring oral 
and eye mu-
co sa 
None PCT- like 
None PCT-like 
No ne EB- like 
None EB- like 
DH-like Minimal 
DH-like None 
None CP- like 
Distribution 
Generalized, oral and 
eye mucosa 
Generalized, oral 
mucosa 
Generalized, oral 
mucosa 
Generalized, oral 
mucosa 
Generalized face, ex-
tremities 
Arms, hands 
Arms, hands 
Generalized with 
acral predomi-
nance 
Generalized with 
acral predomi-
nance, oral mu-
cosa, esophageal 
stenosis 
Generalized, peni le 
and oral mucosa, 
alopecia 
Generalized, oral 
mucosa 
Head, face, neck, 
oral mucosa 
Associated 
diseases 
None 
Diabetes melli-
tus 
Diabetes, 
schizophre-
nia 
Diabetes 
Diabetes 
None 
None 
Multiple endo-
crinopathy 
syndrome 
None 
Juvenile rheu-
matoid ar-
thri tis 
None 
Organic brain 
syndrome 
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Histopathology 
Subepidermal sepa ration cha racte ri zes both inflam matory 
and noninflammato ry les ions. In addi t ion, inflammatory le-
sions, especia lly erythematous plaques with vesiculation, dem-
onstrate edema in the papillary dermis with moderate to intense 
mixed cellula r infiltrat ion composed of neutrophils, monocytes, 
and eosinophils in t he papillary dermis and perivascular con-
nective t issue. Neutrophil s usually predominate as opposed to 
eosinophils which are more commonly encountered in BP. 
Sometimes neutrop hils line up at the ep idermal-dermal junc-
tion in areas of incipient epidermal-dermal sepa ration. Inflam-
matory lesions may resemble BP, show an eos inophil predom-
inance, or on occasion resemble erythema multiforme or DH. 
Noninflammato ry lesions, espec ia lly experimentally- induced 
blisters, may show a sharp cleavage plane beneath t he epidermis 
and the absence of inflammation. 
On electron microscopy, t he most defini t ive ultrastructura l 
lesion is seen in patients with marked skin fragili ty in whom 
an experimental blister is mechanica lly induced. Here the 
cleavage plane occurs in the dermis beneath t he lamina densa 
or anchoring fibril -lamina densa complex. 
Dense, a morphous deposits a re seen in some patients beneath 
t he lamina densa and may be quite extensive (Fig 1) . On 
immunoelectron microscopy, these deposits are heavily stained 
with immune reaction product indicating a significant lgG 
content (Fig 2). 
Immunopathologic Studies 
Direct immunofluorescent studies of les ional and uninvolved 
perilesional skin demonstrate linear deposits of IgG at the 
BMZ. These deposits a re usua lly intense and ex hibit a broad 
fluorescent band. Complement components as well as JgA and 
IgM may be seen a lso bu t are usua lly less in tense than t he IgG. 
Since we regard the demonstration of linea r lgG deposition at 
the BMZ to be essent ia l fo r the diagnosis of EBA of the 
immunopathologic type (dermolytic pemphigoid) , all patients 
exhibit t his finding (Table II) . It may be possible t hat patients 
with very long-standing disease no longe r have lgG ant ibodies 
demonstrable at the BMZ, but we have not obse rved this and 
are unaware of its occurrence in the li terature. 
Circulating IgG ant i-BMZ ant ibodies are found in many 
patients with EBA, although the t rue frequency is unknown. 
The chronological stage of the disease may be an important 
factor. About 25% of the cases with classica l EBA reported in 
the li terature had circulating IgG anti-BMZ ant ibodies whereas 
we found that 4 of 5 patients (80%) with an inflammatory BP-
Iike presentation exhibi ted anti-BMZ ant ibodies. Decreasing 
antibody titers were noted in several patients during t he tran-
FIG 1. Electron micrograph of skin from a patient with class ical 
EBA (Case 8) showing a morphous deposits (D) beneath t he lam ina 
densa (arrow). X 26,000. 
FIG 2. Direct immunoelectron micrograph on the same ski n sample 
as in Fig 1. The deposit (D) beneath t he la mina densa (arrow) is heavily 
stai ned with immune reaction product following a nt ihuman IgG a nt i-
body t reatment which indicates tha t the sublamina densa deposit 
conta ins IgG. x 26,000. 
sit ion from the early inflammato ry to the late classical nonin -
fl ammatory phases. Concomitant t reatment with prednisone 
and immunosuppressive agents may have decreased t he ant i-
body t iter. More extensive studies of all stages of disease will 
be needed to assess the frequency of the circulating antibodies. 
Direct immunoelectron microscopy of perilesional skin is 
essential in distinguishing patients with immunopathological 
EBA from those with diseases such as BP and MP that exhibit 
lamina Iucida immune deposits. In all cases with EBA, t he 
immune deposits have been located below the lamina densa 
(11- 16, Table II). The lamina Iucida is free of immune deposits. 
In the early inflammatory phase, especially in patients with 
BP-like presentations, immune deposits were found overlying 
the lamina densa, particularly the lower portion of the lamina 
densa as well as beneath the lamina densa (Fig 3) . In the sk in 
of patients with long-standing disease, especially with non in -
flammatory lesions, immune deposits may be found deeper 
beneath the lamina densa frequently with a clear zone between 
the uninvolved lamina densa and the immune deposits (Fig 2) . 
In two of our patients examined during the tra nsit ion from 
inflammatory to noninfl ammatory phases (Table I, Cases 2, 3) , 
a shi ft was observed in the loca lization of the immune deposits 
from the lamina densa-sublamina densa zone to exclusively 
deeper immune deposits. 
Using a normal human skin substrate with indirect immu-
noelectron microscopy, the ul t rastructural localization of the 
circulat ing anti-BMZ antibodies was found to be overlying the 
lamina densa and immediately beneath t he lamina densa (Fig 
4). Occasionally immune deposits were also seen deeper but 
never without lamina densa-sublamina densa deposits. The 
antigenic target for these antibodies is a component of normal 
human skin basement membrane located in and beneath t he 
lamina densa. On no occasion have we seen disagreement 
between direct and indirect immunoelectron microscopic find-
ings (i.e., sublamina densa deposits in one and lamina Iucida 
deposits in the other) . 
The variation in the localization of the immune deposits by 
direct immunoelectron microscopy to the lamina densa-sublam -
ina densa area in earli er disease and sublamina densa a rea with 
sparing of the lamina densa itse lf in later disease is interesti ng. 
We can on ly speculate on its development. The lamina densa 
and immediate sublamina densa areas are t he true loca li zation 
of the antigen(s) and is t he site of ant ibody deposition during 
the ini tial phase of the di sease. Later, perhaps associated with 
a decrease in circu lati ng ant ibody, remodeling of the BMZ may 
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TABLE II. Laboratory studies 
Electron Immunofluorescence lmmuno· lmmunoelectron Case Light microscopy microscopy Direct Indirect Blot microscopy 
1 (CM) Subepidermal separation, No deposit Intense linear lgG, Linear lgG, 290 kd Lamina densa-
neutrophil predomi- C' C' 145 kd sublamina 
nance densa 
2 (OK) Subepidermal separat ion, No deposit In tense linear IgG, Linear lgG, 290 kd Lamina densa-
neutrophil predomi- less intense lgA, C' 1:320 145 kd sublamina 
nance lgM den sa 
3 (EC) Subepidermal separation , No deposit Intense lgG, C', Linear lgG 290 kd Lamina densa-
neutrophil predomi- trace lgA, lgM 1:320 145 kd sub lamina 
nance den sa 
4 (JW) Subepidermal separation, No deposit Intense lgG, C' None NO" Lamina densa-
neutrophi l predomi- sublamina 
nance den sa 
5 (OM) Epidermal-basal cell No deposit In tense linear lgG Linear lgG 290 kd Lamina densa-
layer 1:320 145 kd sublamina 
den sa 
6 (CR) Subepidermal sepa rat ion, Amor- Linear IgG, C3 NO NO Sublamina 
noninflammatory phous den sa 
deposit, 
sublam -
ina 
densa 
7 (WS) Subepidermal separation, No deposit • Linear lgG NO NO Sublamina 
noninflam matory dens a 
8(JM) Subepidermal separation, No deposit Linear IgG Linear IgG, 290 kd Lamina densa-
noninflammatory C' 1:40 145 kd sublamina 
densa 
9 (AS) Subepidermal separation , No deposit Linear JgG, C3 IgG 1:160 290 kd Lamina densa-
noninflammatory 145 kd sublamina 
dens a 
10 (JC) De rmal papillary nec ro- Amor- Linear lgG, C' Negative NO Lamina densa-
sis with neutrophil phous sublamina 
predominance deposit, den sa 
sublam-
ma 
den sa 
11 (MM) Dermal papilla ry mi- No deposit Intense linear lgG, lgG 1:40 NO Lamina densa-
croabscess with neu- less intense IgA, sublamina 
trophi l predominance lgM den sa 
12 (MB) Subepidermal separation, No deposit Intense linear lgG Negative NO Lamina densa-
neutrophil predomi- sublamina 
nance den sa 
FIG 3. Direct immunoelectron micrograph of t he perilesional skin 
of a patient with the inflammatory phase of EBA (Case 2) . Immune 
deposit (D) is seen in and beneath the lamina densa. X 14,600. 
FIG 4. Indirect immunoelectron micrograph with circulating lgG 
anti-BMZ antibody from patient with EBA showing immune deposi t 
(D) in and beneath the lamina densa. X 14,600. 
occur with production of new basem e nt membrane above the 
persistent immune deposits. 
Immunoelectron microscopy has prove n very useful in distin-
guishing diseases associated with la mina densa immune depos-
its such as BP a nd MP, a nd those associated with lamina densa 
and subla mina densa deposits as in EBA and bullous SLE. 
However, the limited availability of immunoelectron micros-
copy makes alternative methods employing standard immuno-
t1uorescence techniques desirable. A double immunot1uores-
cence procedure for distinguishing between lamina densa and 
sublamina densa deposits has recently been reported [21) . A 
second method employing standard indirect immunot1uores-
cence uses a substrate of normal human skin separated through 
the lamina Iucida by incubation in 1 M naCI (22] . The latter 
procedure has proved especially useful because of its ease of 
employment. Using the salt split-skin substrate, anti lamina 
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Iucida ant ibodies bind to either the epidermal or epidermal 
anti lamina densa or sublamina densa ant ibodies bind only to 
t he dermal side. In a recent survey of BP and EBA sera 
comparing indirect immunofluorescence with salt spli t-skin 
substrate and immunoelectron microscopy, complete agree-
ment was found between the two methods regarding t he local-
ization of t he imm une deposits [16]. 
EPIDERMOLYSIS BULLOSA ACQUISITA ANTIGEN 
Identification and Partial Characterization of EBA Antigen 
T he component of skin basement membrane that is target 
fo r the ant ibodies in t he serum of patients with EBA (EBA 
ant igen ) was ident ified in a crude BMZ extract prepared fro m 
human skin (23). S kin slices were incubated in 1 M sodium 
chloride at 4 oc for 3-4 days and separated into epidermal and 
dermal components at the level of the lamina Iucida. Basement 
membrane exposed on the surface of the dermis was extracted 
wit h 8 M urea and 0.3 M beta- mercaptoethanol in Tris buffer. 
T he crude BMZ extract contained numerous protein bands on 
sodium dodecyl sulfate-polyac rylamide gel electrophoresis 
(SDS-PAGE ) stained wit h Commassie blue dye . Following 
t ransfer of the proteins to ni t rocellulose paper and reaction 
wit h serum of patients wit h EBA-IP (Western immunoblot 
assay), only 2 protein bands were seen: a major 290 kilodaltons 
(kd) and a minor 145 kd prote in (Fig 5). These proteins iden-
ti fi ed by EBA sera were di stinct from other known basement 
membrane components and connective t issue macromolecules 
and were specific for EBA-IP. The 290 kd and 145 kd proteins 
were ident ified only by EBA sera and not by a variety of other 
disease- related sera fro m patients wit h BP, DH, herpes gesta-
tionis, and pemphigus, or normal human, goat, and rabbit sera. 
Moreover, ant ibodies specific fo r anchoring fibril s, elastin, lam-
inin , fibronectin and type IV collagen failed to bind to t he 290 
kd or 145 kd p roteins in Western immunoblot assays. In addi-
tion, the EBA ant ibodies recognized only the two protein bands 
in the basement membrane extract and did not bind to a variety 
of purified basement membrane components or connective 
290 
- -
145 
1 H3a EBA 
FIG 5. Western immunoblot of crude BMZ extract wi th binding of 
mouse monoclonal ant ibody (H3a) a nd polyclonal serum from patient 
with epide rmolysis bullosa acquisita (EBA) to 290 kd a nd 145 kd 
p roteins. 
t issue molecules including laminin, elastin, fi bronectin, colla-
gen types I, IV and V, or to epidermal cell extracts. 
In order to determine whether t issue-bound ant ibody derived 
from patients wit h EBA ident ified t he same ant igen , ant ibodies 
were eluted from t he blister roofs of an EBA patient that 
demonstrated characteristic linear IgG fl uorescence at t he ep-
idermal-dermal junction. T he eluted ant ibodies were demon-
strated by indirect immunofluorescence to yield fluorescent 
staining on the dermal side of BMZ of sa lt-spli t skin. Moreover, 
the eluted t issue-bound ant ibodies recognized the same 290 kd 
protein that was ident ified by the patient serum using Western 
immunoblot assays. T his demonstrated t hat the seru m and 
tissue-bound ant ibodies recognize the same ant igen. 
Reduction was required for the proteins to en ter polyacryl-
amide gel indicating that t he native molecule is greater than 
800 kd in size and is probably disulfi de cross-linked. Stains 
specific fo r sugars suggest that t he 290 kd and 145 kd proteins 
are glycoproteins. 
Recent ly, a mouse monoclonal ant ibody, H3a directed aga inst 
the EBA ant igen was obtained using hydridoma techniques 
[24] . The crude BMZ extract described above was used as the 
immunizing ant igen. On immunofluorescence, the monoclonal 
antibody localized to t he epidermal-dermal junction of human 
skin . By immunoelectron microscopy, immune deposits were 
present in and immediately subjacent to the lamina densa, a 
distribut ion ident ical to the polyclonal sera of patients wit h 
EBA-IP. SDS-PAGE followed by Western immunoblot assays 
showed t hat the monoclonal ant ibody recognized 290 and 145 
kd ant igens present in the immunizing BMZ extract, ident ical 
with the EBA ant igen recognized by polyclonal sera. T he ob-
servation that the 290 and 145 kd proteins reacted with t he 
monoclonal ant ibody indicates that both proteins share a com-
mon ant igenic determinant. 
Furt her studies on the characterization of EBA antigen(s) 
has been limi ted by the di fficul ty of obtaining sufficient quan-
t it ies of purified antigen. Although the molecular weight deter-
minations of the two proteins, 290 and 145 kd, suggest a simple 
monomer-dimer relationship, enzyme degradation studies in -
dicate t hat t his is probably not the case. T he 290 kd p rotein is 
sensitive to bacterial collagenase, which suggests t hat it prob-
ably has a collagenous component whereas the 145 kd protein 
is not degraded by collagenase. V -8 protease peptide mapping 
studies also indicate a difference in the two proteins. T hese 
studies show t hat EBA ant igen is a newly recognized basement 
membrane component present in adul t human skin, localized 
to the lower port ion of t he lamina densa and to t he area 
immediately subjacen t to the lamina densa. The EBA ant igen 
in its native state is probably a large macromolecule composed 
of 290 and 145 kd subunits, although its molecular organization 
is unknown at this t ime. 
Distribution of EBA Antigen 
The organ-specific and phylogenetic distribut ion of EBA 
ant igen was determined using polyclonal sera from patients 
with EBA and the mouse monoclonal antibody, H3a. T he 
polyclonal human sera and mouse monoclonal ant ibody had an 
ident ical distribut ion in all tissues tested except in the mouse 
where staining with the mouse monoclonal ant ibody was ab-
sent. The polyclonal and monoclonal EBA ant ibodies reacted 
with a basement membrane ant igen in all mammalian skin but 
not in avian, amphibian, or reptilian skin. Both ant ibodies were 
distributed at the BMZ of skin , buccal mucosa, tongue, upper 
and lower esophagus, but not in kidney, urinary bladder, lymph 
nodes, placenta, amnion, or blood vessels. EBA ant igen is 
limited in its distribut ion to the basement membranes of mam-
malian stratified squamous epit helia of both nonkeratinizina 
and keratin izing types. " 
The embryonic development of EBA ant igen was studied in 
human embryos from 7-20 weeks gestational age, using both 
monoclonal and polyclonal EBA ant ibodies. EBA ant igen ap-
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pears first at t he 8th week of gestational age as a broad zone of 
granu lar depos it ion over the lower portion of the epithelium 
and the epithelia l-mesenchymal interface. Later, by the 10th-
11th week , condensation of t he depos it is see n to form a more 
dense band of depos ition at t he interface and by the 12t h - 15th 
week , a dense broad linear band s imilar to the pattern in adult 
skin is see n . · 
BULLOUS LUPUS ERYTHEMATOSUS- A SPECIAL 
CASE OF REACTIVITY TO THE EBA ANTIGEN 
Patie nts have been reported wi t h a general ized bullous dis-
ease resemblin g BP or DH in association with SLE [25-31] . 
Although the clin ical express ion of these patie nts may be 
va riab le, t he labo ratory findings have bee n fairly uniform. The 
immunohistology feature s linear IgG and complement depos i-
tion at the BMZ. U ltrastructurally, t he lgG depos its are located 
below the lamina densa [28,29,31]. A circu lating BMZ antibody 
had not bee n found previously usin g routin e immunof1uores-
cence wi t h no rma l human sk in substrates. 
Recently, we have found that t hree out of four bullous lupus 
erythematosus patients s how a circu lat ing a nti-BMZ antibody 
when 1 M sodium chloride-separated sk in is used as a substrate 
in immunofluorescence stud ies. Binding is on t he dermal side 
of the separated skin. In addition, the immunoglobulin locali-
zation is limited to the skin and not vascu lar basement mem-
branes. U lt rastructurally, antibodies localize to t he lamina 
densa a nd to t he sublamina densa zone and bind to 290 kd and 
145 kd dermal proteins in W estern immunoblots . In addition, 
one out of 20 patients with SLE a nd no bli sters showed a 
s imilar antibody. In one case of bullous SLE, a t issue-deposited 
IgG a n t ibody of t he same spec ificity was found in e luates of 
immune deposits from the skin . These studies show t hat at 
least so me patients with bullous SLE have a ntibodies with 
reactivity to EBA a n tigen, both circu lating and deposited m 
their tissue. 
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